Related content

Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir

By Millán Olga  

Clinical Pharmacokinetics, Vol. 44, Iss. 5, 2005-01 ,pp. : 525-538

Adis International

Access to resources Recommend Favorite

Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients

By Dailly Eric   Tribut Olivier   Tattevin Pierre   Arvieux Cédric   Perré Philippe   Raffi François   Jolliet Pascale  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 523-526

Springer Publishing Company

Access to resources Recommend Favorite

Effect of Gender and Race on the Pharmacokinetics of Pentamidine in HIV-Infected Patients

By Conte J.E.J.   Duncan S.   McKenna E.   Zurlinden E.  

Clinical Drug Investigation, Vol. 17, Iss. 4, 1999-04 ,pp. : 293-299

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis

By López-Cortés L.F.  

Clinical Pharmacokinetics, Vol. 41, Iss. 9, 2002-01 ,pp. : 681-690

Adis International

Access to resources Recommend Favorite

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

By Elens Laure   Vandercam Bernard   Yombi Jean-Cyr   Lison Dominique   Wallemacq Pierre   Haufroid Vincent  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1223-1234

Future Medicine

Access to resources Recommend Favorite